Please login to the form below

Not currently logged in
Email:
Password:

plaque psoriasis

This page shows the latest plaque psoriasis news and features for those working in and with pharma, biotech and healthcare.

Amgen raises forecasts after closing $13.4bn Otezla deal

Amgen raises forecasts after closing $13.4bn Otezla deal

Amgen lost no time completing its acquisition of psoriasis blockbuster Otezla in the wake of the Bristol-Myers Squibb/Celgene merger, and promptly raised its 2019 sales forecasts. ... plaque psoriasis that could also expand the eligible patient population

Latest news

  • Novartis’ Cosentyx misses the mark in Humira head-to-head Novartis’ Cosentyx misses the mark in Humira head-to-head

    It is also approved for psoriatic arthritis and plaque psoriasis. The Swiss pharma giant  posted a 27% increase in Cosentyx sales in its recent third quarter earnings, with the drug bringing

  • Janssen files Tremfya for psoriatic arthritis in Europe Janssen files Tremfya for psoriatic arthritis in Europe

    Hopes to extend use beyond plaque psoriasis. Johnson &Johnson’s Janssen division has filed its immunology therapy Tremfya for psoriatic arthritis (PsA) in Europe, hoping to extend use of the drug ... beyond plaque psoriasis.

  • J&J's Tremfya filed for approval in US for psoriatic arthritis J&J's Tremfya filed for approval in US for psoriatic arthritis

    With a successful  head-to-head trial against Novartis’ Cosentyx in plaque psoriasis under its belt, J&J’s drug has been established as a significant contender in the crowded field ... However, J&J has been subject to another head-to-head trial –

  • FDA clears Lilly’s Taltz for ankylosing spondylitis FDA clears Lilly’s Taltz for ankylosing spondylitis

    Taltz (ixekizumab) – an interleukin-17 inhibitor previously approved for psoriasis and psoriatic arthritis – now has the same diseases on its label as class leader Cosentyx (secukinumab) which grew by almost a ... The drugmaker has also just

  • Amgen snaps up Celgene’s Otezla for $13.4bn Amgen snaps up Celgene’s Otezla for $13.4bn

    Otezla is currently approved for three indications in the US - moderate-to-severe plaque psoriasis (in patients eligible for phototherapy or systemic therapy), adults with active psoriatic arthritis; and the recently ... psoriasis and paediatric plaque

More from news
Approximately 6 fully matching, plus 93 partially matching documents found.

Latest Intelligence

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    It gained US approval for moderate to severe plaque psoriasis in April, and for EU approval in that indication in early May. ... In May last year, approval for Skyrizi was filed in Japan for plaque psoriasis, psoriatic arthritis, pustular psoriasis and

  • Pharma deals continue to slide Pharma deals continue to slide

    Pre-registration (US) topical high potency steroid for moderate to severe plaque psoriasis.

  • 'Nothing about us without us' 'Nothing about us without us'

    Similarly, Novartis - which issued a patient declaration committing, among other things, to inviting patient input early on in their clinical trial process - recently invited people living with plaque psoriasis to attend

  • Deal Watch March 2017 Deal Watch March 2017

    Merck KGaA has partnered its product M1095 (ALX-0761), for plaque psoriasis, to Avillion.

  • Deal Watch July 2016 Deal Watch July 2016

    The product completed Phase 3 studies in moderate to severe plaque psoriasis in May 2016 and announced that the primary endpoints had been met. ... Acquisition. 78. Sun Pharma/ Almirall. Tildrakizumab (IL-23p19 inhibitor) - psoriasis. Licence.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Body image and mental health: The psoriasis connection

    2. This most often causes plaque psoriasis, where red, raised and scaly patches of skin may appear anywhere on the body, in one location or in many, or someone may develop ... For a while psoriasis did have a negative effect on my body image.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....

Infographics